CD95L-DCs induced increased allospecific TH1-type response and cytotoxic activity in an MHC class I disparate model.
(A) Four to 6 bm13 mice received 3 × 105 lpr/lpr control or CD95L-DCs in footpad. MLCs were performed 5 days later with draining LN cells and either syngeneic (bm13; white bars), allogeneic (lpr/lpr; black bars), or third-party (BALB/c; gray bars) spleen cells. Results were expressed as mean ± SEM (*P < .03). Similar results were obtained in 2 experiments. NT indicates nontreated mice. (B) Donor-type– (left panel) or third-party– (right panel) specific CTL activity was evaluated after the same control (○) or CD95L (▴) DC treatment. ▵ represent CD95L-DCs with RB6-8C5 (anti-Gr1) mAbs treatment. Results are mean percentage of lysis ± SEM of 3 to 4 individual mice per group (*P < .02 compared with the control-DC group and *P < .004 compared with anti-GR1–treated group with the 2-tailed Student ttest). Similar results were obtained in 3 separate experiments.
